1. Academic Validation
  2. RBM47 as a potential therapeutic target for thyroid-associated ophthalmopathy

RBM47 as a potential therapeutic target for thyroid-associated ophthalmopathy

  • Int Immunopharmacol. 2025 Feb 6:147:113955. doi: 10.1016/j.intimp.2024.113955.
Ru Zhu 1 Fei Chen 2 Bo-Wen Wang 2 Ying Jin 2 Jun-Jie Yang 2 Bing-Jie Shi 2 Yu-Ting Chen 2 Fa-Gang Jiang 3 Xing-Hua Wang 4
Affiliations

Affiliations

  • 1 Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Aier Eye Hospital of Wuhan University, Wuhan 430060, China.
  • 2 Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • 3 Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: fgjiang@hust.edu.com.
  • 4 Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: xinghua_wang@hust.edu.cn.
Abstract

RNA-binding motif 47 (RBM47) is a recently identified RNA-binding protein involved in early vertebrate development, immune homeostasis, and Cancer development. This study examined the biological functions of RBM47 in thyroid-associated ophthalmopathy (TAO). Orbital fibroblasts (OFs) were obtained from the control (n = 6) and TAO groups (n = 6). Protein and gene expression in the obtained samples were investigated using immunohistochemistry, western blotting (WB), and RT-PCR. OFs with RBM47 knockdown were established using small interfering RNA. Subsequently, Oil Red O staining, WB, and RT-PCR were performed to assess adipogenesis in the OFs. The IL-1β-induced expression of proinflammatory molecules and hyaluronan (HA) was determined using enzyme-linked immunosorbent assay and RT-PCR. Moreover, TGF-β-induced fibrosis was evaluated using scratch assays, RT-PCR, and WB. RBM47 expression was markedly increased in orbital tissues and OFs obtained from individuals with TAO. RBM47 knockdown decreased adipogenesis and fibrosis in OFs, and downregulated the levels of insulin-like growth factor 1 receptor (IGF-1R), proinflammatory molecules, and HA. Furthermore, low RBM47 expression downregulated IGF-1R, which subsequently inhibited adipocyte differentiation by decreasing extracellular signal-regulated kinase signalling. These findings indicate that RBM47 may be involved in the regulation of adipogenesis, inflammation, HA production, and fibrosis, highlighting its potential of RBM47 as a therapeutic target for TAO.

Keywords

Adipogenesis; Autoimmune disease; Orbital fibroblasts; RNA-binding protein; Thyroid-associated ophthalmopathy.

Figures
Products
Inhibitors & Agonists
Other Products